Conversion to JCV Positivity Common With Natalizumab in MS Conversion to JCV Positivity Common With Natalizumab in MS
A study including longitudinal analysis of patients with MS treated with natalizumab shows no link between duration of treatment and conversion to JCV antibody positivity or PML. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Tysabri May be Tx Option in Kids With MS (CME/CE)
(MedPage Today) -- Italian registry study suggests treatment is safe and effective (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - September 30, 2015 Category: Pediatrics Source Type: news
Disease modifying drugs
A Cochrane review of disease modifying drugs for relapsing MS found that the best at reducing relapse in the first two years of treatment were alemtuzumab, mitoxantrone, natalizumab and fingolimod. The best at reducing the build up of disability in the same period were mitoxantrone, alemtuzumab, and natalizumab. The review criticises the lack of long-term evidence for efficacy and side effects.
MS News Today
Disease modifying drugs for relapsing MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 21, 2015 Category: Neurology Source Type: news
Switching From Natalizumab to Fingolimod in RRMSSwitching From Natalizumab to Fingolimod in RRMS
This study aims to improve our understanding of drug-induced immune changes and potential disease exacerbation during switch-over from natalizumab to fingolimod in treatment of RRMS. BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
MS drugs during pregnancy
A review of different studies looking at the effects of Betaferon, teriflunomide and natalizumab on women with MS who become pregnant. Although the numbers are relatively small, Results suggest that there was no increase in spontaneous abortions or birth abnormalities.
MS Research Australia
Pregnancy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 10, 2015 Category: Neurology Source Type: news
Tysabri and cognition
A small Italian study found that after three years, people with MS taking natalizumab (Tysabri) did better on tests of cognition as well as showing reduced relapse rates and stable EDSS.
MS News Today
Cognition and cognitive symptoms - A to Z of MS
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 12, 2015 Category: Neurology Source Type: news
Natalizumab SC Similar to IV Every 4 Weeks for MSNatalizumab SC Similar to IV Every 4 Weeks for MS
A randomized comparison finds subcutaneous and intravenous administration of natalizumab similar when given every 4 weeks, but the company, Biogen, has decided not to pursue the product after all. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 22, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
What's the Optimal Washout After Natalizumab in MS? What's the Optimal Washout After Natalizumab in MS?
A new study suggests that shorter washout periods may be better than longer ones, and even that no washout may be needed at all. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 15, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Timing the switch from Tysabri to Gilenya
A study has been published showing that a shorter washout time when changing from treatment with natalizumab (Tysabri) to fingolimod (Gilenya) reduces the risk of relapse.
MS Research Australia
Natalizumab (Tysabri) - A to Z of MS
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 8, 2015 Category: Neurology Source Type: news
No Surprises with Tysabri-Tecfidera Switch
(MedPage Today) -- Discontinuation rates for both agents were in line with those seen in clinical trials (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 2, 2015 Category: Journals (General) Source Type: news
'We expected our daughter's MS but it still felt like a bombshell'
Childhood multiple sclerosis often goes undetected but Lucy Wood's early diagnosis at the age of five has been crucial in reducing her disability over time (Source: The Telegraph : Health Advice)
Source: The Telegraph : Health Advice - May 11, 2015 Category: Consumer Health News Tags: Professor Susan Kirk myelin University of Manchester paediatric MS Multiple sclerosis Tysabri Dr Cheryl Hemingway Source Type: news
Tysabri Review Launched in EuropeTysabri Review Launched in Europe
New scientific data have prompted experts to see whether changes are warranted for managing risks for progressive multifocal leukoencephalopathy in patients taking natalizumab. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 8, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Gilenya fails in progressive MS / Tysabri injections
A round up of presentations from AAN includes a study that found fingolimod (Gilenya) didn't slow progressive MS and research that shows injections of natalizumab (Tysabri) were as effective as infusions. Presented at the American Academy of Neurology (AAN) meeting.
MedPage Today
Fingolimod (Gilenya) - A to Z of MS
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 23, 2015 Category: Neurology Source Type: news
Increasing Tysabri Dosing Interval May Cut PML Risk
(MedPage Today) -- No sacrifice of efficacy seen in retrospective analysis. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - April 22, 2015 Category: Journals (General) Source Type: news
Extending natalizumab up to 8 weeks shown safe and effective in patients with multiple sclerosis, report says
Extending the dose of natalizumab from four weeks up to eight weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy, researchers report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 20, 2015 Category: Science Source Type: news
